efficacy and safety of sintilimab with anlotinib as first-line therapy for advanced non small cell lung cancer用Anlotinib作为晚期非小细胞肺癌NSCLC一线疗法功效安全性.pdf

Efficacyandsafetyofsintilimabwithanlotinib

asfirst-linetherapyforadvancednon-smallcell

lungcancer(NSCLC)

1*11111

BaohuiHan,TianqingChu,RunboZhong,HuaZhong,BoZhang,WeiZhang,Chunlei

111

Shi,JialinQian,YuchenHan

1.ShanghaiChestHospital,ShanghaiJiaotongUniversity,Shanghai,;*Correspondingauthor

BaohuiHan,ShanghaiChestHospital,

Disclosure

BaohuiHan

Speakersbureau:

ￚAstraZenecaPlc.

ￚEliLillyandCompany.

Consultant:

ￚF.Hoffmann-LaRocheLtd.

ￚAstraZenecaPlc.

Researchfunding:

ￚInnoventBiologicsCo.,Ltd;

ￚChiaTaiTianqingPharmaceuticalGroupCo.,Ltd.

BaohuiHan,ShanghaiChestHospital,

Background

Sintilimab:PD-1ReceptoroccupancySintilimabin1LadvancedNSCLC:

•Thesynergyeffectofimmunotherapyandanti-angiogenictherapyORR60%

hasbeenprovedbyseveralstudiessuchasIMPOWER1501,2

Squamous64.7%

•Sintilimab:anovelfullyhumanIgG4anti-PD-1monoclonalantibody,

hasshowedanti-tumoractivitiesinadvancedNSCLC3,4